Literature DB >> 15676102

Prevention of embolism among patients with atrial fibrillation.

Harold P Adams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15676102     DOI： 10.1007/s11910-005-0017-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  10 in total

Review 1.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  G W Albers; P Amarenco; J D Easton; R L Sacco; P Teal
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.

Authors:  Job Harenberg; Jörg Ingrid; Fenyvesi Tivadar
Journal:  Isr Med Assoc J       Date:  2002-11       Impact factor: 0.892

Review 3.  Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.

Authors:  R G Hart; J L Halperin
Journal:  Ann Intern Med       Date:  1999-11-02       Impact factor: 25.391

4.  A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

Authors:  J P Mohr; J L Thompson; R M Lazar; B Levin; R L Sacco; K L Furie; J P Kistler; G W Albers; L C Pettigrew; H P Adams; C M Jackson; P Pullicino
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

5.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.

Authors:  Bengt I Eriksson; David Bergqvist; Peter Kälebo; Ola E Dahl; Siv Lindbratt; Anders Bylock; Lars Frison; Ulf G Eriksson; Lennart Welin; David Gustafsson
Journal:  Lancet       Date:  2002-11-09       Impact factor: 79.321

6.  Warfarin use among patients with atrial fibrillation.

Authors:  L M Brass; H M Krumholz; J M Scinto; M Radford
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

7.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

Authors:  M D Ezekowitz; S L Bridgers; K E James; N H Carliner; C L Colling; C C Gornick; H Krause-Steinrauf; J F Kurtzke; S M Nazarian; M J Radford
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

8.  Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

Authors:  Jonathan L Halperin
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

9.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Authors:  Sam Schulman; Karin Wåhlander; Torbjörn Lundström; Solveig Billing Clason; Henry Eriksson
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.